BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11792066)

  • 1. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
    Masuoka M; Yoshimuta T; Hamada M; Okamoto M; Fumimori T; Honda J; Oizumi K; Itoh K
    Viral Immunol; 2001; 14(4):369-77. PubMed ID: 11792066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.
    Akiyama Y; Maruyama K; Mochizuki T; Sasaki K; Takaue Y; Yamaguchi K
    Immunol Lett; 2002 Aug; 83(1):21-30. PubMed ID: 12057851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells.
    Provenzano M; Mocellin S; Bettinotti M; Preuss J; Monsurrò V; Marincola FM; Stroncek D
    J Immunother; 2002; 25(4):342-51. PubMed ID: 12142557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.
    Solache A; Morgan CL; Dodi AI; Morte C; Scott I; Baboonian C; Zal B; Goldman J; Grundy JE; Madrigal JA
    J Immunol; 1999 Nov; 163(10):5512-8. PubMed ID: 10553078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.
    Kuzushima K; Hayashi N; Kimura H; Tsurumi T
    Blood; 2001 Sep; 98(6):1872-81. PubMed ID: 11535524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients.
    Akiyama Y; Tai S; Komiyama M; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y
    Oncol Rep; 2009 Jul; 22(1):185-91. PubMed ID: 19513522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.
    La Rosa C; Wang Z; Brewer JC; Lacey SF; Villacres MC; Sharan R; Krishnan R; Crooks M; Markel S; Maas R; Diamond DJ
    Blood; 2002 Nov; 100(10):3681-9. PubMed ID: 12393676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
    Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
    Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.
    Kondo E; Akatsuka Y; Kuzushima K; Tsujimura K; Asakura S; Tajima K; Kagami Y; Kodera Y; Tanimoto M; Morishima Y; Takahashi T
    Blood; 2004 Jan; 103(2):630-8. PubMed ID: 12947002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele.
    Provenzano M; Lim JB; Mocellin S; Monsurro V; Bettinotti M; Marincola FM; Stroncek DF
    Transfusion; 2003 Nov; 43(11):1567-74. PubMed ID: 14617317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer.
    Akiyama Y; Kuzushima K; Tsurumi T; Yamaguchi K
    Immunol Lett; 2004 Sep; 95(2):199-205. PubMed ID: 15388261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
    Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
    Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes.
    Lim JB; Provenzano M; Kwon OH; Bettinotti M; Caruccio L; Nagorsen D; Stroncek D
    Exp Hematol; 2006 Mar; 34(3):296-307. PubMed ID: 16543064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries.
    La Rosa C; Krishnan R; Markel S; Schneck JP; Houghten R; Pinilla C; Diamond DJ
    Blood; 2001 Mar; 97(6):1776-86. PubMed ID: 11238120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
    Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
    J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ suppressor and cytotoxic T cells recognize the same human leukocyte antigen-A2 restricted cytomegalovirus peptide.
    Qin H; Vlad G; Cortesini R; Suciu-Foca N; Manavalan JS
    Hum Immunol; 2008 Nov; 69(11):776-80. PubMed ID: 18848854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of host immunity to cytomegalovirus pp150 (UL32).
    La Rosa C; Wang Z; Lacey SF; Markel SF; Sharma MC; Martinez J; Lalimarmo MM; Diamond DJ
    Hum Immunol; 2005 Feb; 66(2):116-26. PubMed ID: 15694996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.
    McLaughlin-Taylor E; Pande H; Forman SJ; Tanamachi B; Li CR; Zaia JA; Greenberg PD; Riddell SR
    J Med Virol; 1994 May; 43(1):103-10. PubMed ID: 8083644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.